TORONTO, ON --(Marketwired - March 17, 2017) - The live broadcast taking place on Wednesday, April 5, 2017, features Michael Cook, Principal, Epidemiology and Dhvani Shah, Lead Health Economist both from ICON Commercialisation & Outcomes as presenters.
Join the speakers to learn about the best practices for developing a comprehensive health economic and epidemiologic evidence strategy and evidence generation plan that is targeted to meet the needs of regulators and payers.
Get insights on the different types of health economic and epidemiologic evidence that can be used to optimise the success of regulatory and HTA submissions, the typical timeframes for generating each piece of evidence, and how to address challenging HTA submission scenarios, such as when:
- Sponsors only submit Phase II data for accelerated regulatory approval
- Clinical trials did not demonstrate clinical/statistical significance in their primary endpoint
- Clinical trials effect sizes did not meet the existing cost-effectiveness thresholds
Regulators and payers have placed new demands on the pharmaceutical and biotechnology industry to provide health economic and epidemiologic evidence, in addition to clinical trials data, to demonstrate the value and safety of a new product. A well-developed evidence strategy is an important part of the clinical development program, and is a key component of regulatory and HTA submission planning.
Planning for regulatory and HTA submissions requires strategic foresight into what regulators and payers will consider most influential in their respective reviews. An important step is to identify the health economic and epidemiology evidence that needs to be collected during the clinical development program, and what evidence may already exist. A landscape assessment, done when the investigational product is in early clinical development, can identify evidence sources that may already exist in the published literature, and the availability of:
- Background epidemiologic data on the incidence/prevalence of the disease
- Characteristics and comorbidities of the target patient population, and the burden of disease
- Current treatment guidelines for the disease
- HTA approaches used for other therapies with the same indication
- Current and future market access and pricing considerations
- Data on the humanistic and economic impacts on the disease
Also in early clinical development, it is important to define the aspirational value message for the investigational product in terms of unmet medical need, clinical value, human value, or economic value. By aligning the health economic and epidemiologic evidence strategy with the aspirational value message, the relevance of each piece of evidence becomes clear.
Best Practices and Challenges
- Identify Evidence Gaps Early
- Solicit Early Stakeholder Feedback
- Be Ready for Challenging HTA Submissions
For more information or to register for this free webinar visit: Optimise Your Regulatory & HTA Submissions with a Comprehensive Health Economic & Epidemiologic Evidence Strategy
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx
Image Available: http://www.marketwire.com/library/MwGo/2017/3/16/11G133365/Images/ICON_Logo_Mar2017-784c521a7dadaaeeb6c517a9ab1db88c.jpg